C03CA04 - Torasemide |
Possibly porphyrinogenic |
PSP |
Rationale
Metabolised by CYP2C9. Torasemide is a sulfonamide congener, drug group often incriminated in porphyric attacks. One reference warns against the drug on grounds of insufficient data.
Chemical description
Sulfonamide congener.
Therapeutic characteristics
Sulfonamide loop-diuretic.
Metabolism and pharmacokinetics
Extensively CYP-metabolized in the liver, CYP2C9 is probably the most important isoenzyme. No data pointing to CYP-induction.
Personal communication
None
Published experience
None
IPNet drug reports
Uneventful use reported in 2 patients with acute porphyria.
Similar drugs
References
# | Citation details | PMID |
---|---|---|
* | Scientific articles | |
1. | Torasemide. A review of its pharmacological properties and therapeutic potential.
Friedel HA, Buckley MM. Drugs. 1991 Jan;41(1):81-103. |
1706990 |
2. | Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes.
Miners JO, Coulter S, Birkett DJ, Goldstein JA. Pharmacogenetics. 2000 Apr;10(3):267-70. |
10803683 |
3. | Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism.
Miners JO, Rees DL, Valente L, Veronese ME, Birkett DJ. J Pharmacol Exp Ther. 1995 Mar;272(3):1076-81. |
7891318 |
Tradenames